FDA approves landmark pancreatic cancer drug that’s shown to improve survival
The U.S. Food and Drug Administration approved daraxonrasib, branded as Rasonque, for advanced pancreatic cancer, marking a significant breakthrough. The drug, which blocks a mutated protein linked to tumor growth, nearly doubled patients' survival time to a median of 13.2 months compared to 6.7 months with chemotherapy. The approval is expected to impact treatment options for approximately 67,000 new patients diagnosed annually.